Introduction Neonatal opioid withdrawal syndrome (NOWS) often arises in infants born to
mothers who used opioids during pregnancy. Morphine, methadone, and buprenorphine are …

Objectives To assess whether a shorter length of stay (LOS) is associated with a higher risk
of readmission among newborns with neonatal abstinence syndrome (NAS) and examine …

Aims: Epigenetic variation of DNA methylation of the mu-opioid receptor gene (OPRM1) has
been identified in the blood and saliva of individuals with opioid use disorder (OUD) and …

Background Neonatal abstinence syndrome (NAS) due to opioid withdrawal may result in
disruption of the mother‐infant relationship, sleep‐wake abnormalities, feeding difficulties …

Pregnant women with opioid use disorder (OUD) are at risk of overdose, infectious diseases,
and inadequate prenatal care. Additional risks include adverse pregnancy and infant …

Objective To increase the usage rate of mothers' own milk (MOM) among neonates with
prenatal opioid exposure from a baseline average of 47% to an average of 75% over two …

Objective Our cost-effectiveness analysis investigated rooming-in versus not rooming-in to
determine optimal management of neonates with neonatal opioid withdrawal (NOW). Study …

Objectives: To reduce transfers to the neonatal intensive care unit (NICU) for neonates with
opioid withdrawal while also reducing length of stay and pharmacologic intervention, and …

Although prenatal opioid exposure and postnatal withdrawal (neonatal abstinence
syndrome) are associated with infant neurobehavioral deficits, little is known about the …

Background: The prevalence of neonatal abstinence syndrome is increasing, but the
number and quality of clinical practice guidelines available are unknown. This systematic …